阿司匹林使用与年龄相关性眼病研究中年龄相关性黄斑变性进展的关联:年龄相关性眼病研究2第20号报告
在AREDS和AREDS2两项口服补充剂临床试验的前瞻性队列中,按倾向评分1:1匹配阿司匹林使用者与非使用者后分析,未发现阿司匹林使用与晚期年龄相关性黄斑变性(AMD)或其亚型进展存在显著关联。作者认为,当有医学指征时,AMD患者无需因此避免使用阿司匹林。
要点
- AREDS匹配1950人、AREDS2匹配1694人,中位随访分别为10.1年和5.0年。
- 两个研究中阿司匹林高倾向评分五分位5与五分位1比较,进展至晚期AMD的风险比均未达统计学显著。
- 作者结论认为阿司匹林使用与晚期AMD或其亚型进展无显著关联。
核心结论
- 在AREDS和AREDS2两个队列中,阿司匹林使用与进展至晚期AMD或其亚型均无显著关联。
- 作者认为,当有医学指征时,AMD患者无需因此避免使用阿司匹林。
研究设计与样本
- 两项前瞻性队列研究,嵌套于两项口服补充剂治疗年龄相关性眼病的对照临床试验中。
- 研究对象为55至80岁的AREDS参与者和50至85岁的AREDS2参与者。
- 按研究基线时双眼均无晚期AMD(地图样萎缩或新生血管性AMD)的参与者,分别计算阿司匹林使用的倾向评分,使用者与非使用者按倾向评分1:1匹配(AREDS和AREDS2分别进行)。
- 对匹配后的参与者进行比例风险回归并校正年龄,评估阿司匹林倾向评分与进展至晚期AMD及其亚型的关联。
- 主要结局指标为中央阅片评估的彩色眼底照相上进展至晚期AMD。
主要发现
- 3734名符合条件的AREDS参与者中1049名(28.1%)使用阿司匹林,2403名符合条件的AREDS2参与者中1198名(49.9%)使用阿司匹林。
- 倾向评分匹配后,两个研究中使用者与非使用者的特征相似。
- 匹配后的1950名AREDS参与者和1694名AREDS2参与者中,中位随访分别为10.1年和5.0年,进展至晚期AMD、地图样萎缩或新生血管性AMD的人数在AREDS分别为454例(23.3%)、345例(17.7%)和278例(14.3%),在AREDS2分别为643例(38.0%)、402例(24.6%)和341例(20.1%)。
- 阿司匹林使用倾向评分五分位5(最高倾向)与五分位1(参照)比较,进展风险比在AREDS分别为1.17(P=0.35)、1.24(P=0.25)和0.95(P=0.81),在AREDS2分别为1.26(P=0.09)、1.46(P=0.03)和1.12(P=0.58)。
- 在两个研究中,五分位2至5对3种结局中的任何一种均未观察到与进展至晚期AMD的显著关联。
临床怎么用
- 作者结论认为,当有医学指征时,AMD患者无需因此避免使用阿司匹林。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the potential association between aspirin use and progression of age-related macular degeneration (AMD). DESIGN: Two prospective cohort studies within 2 controlled clinical trials of oral supplementation for age-related eye disease. PARTICIPANTS: Age-Related Eye Disease Study (AREDS) participants 55 to 80 years of age and AREDS2 participants 50 to 85 years of age. METHODS: Propensity scores for aspirin use were calculated for AREDS and AREDS2 participants separately by logistic regression. Of the participants without late AMD (geographic atrophy [GA] or neovascular AMD) in either eye at study baseline, aspirin users were matched 1:1 with nonusers by propensity score (separately for AREDS and AREDS2). Proportional hazards regression was performed, adjusting for age, on the matched participants to evaluate associations between aspirin propensity score and progression to late AMD (and its subtypes). MAIN OUTCOME MEASURES: Progression to late AMD on color fundus photographs, graded centrally. RESULTS: Of the 3734 eligible AREDS participants, 1049 (28.1%) were taking aspirin, and of the 2403 eligible AREDS2 participants, 1198 (49.9%) were taking aspirin. After matching by propensity score, the characteristics of the users and nonusers were similar in both studies. Of the 1950 matched AREDS participants and 1694 matched AREDS2 participants, over a median follow-up of 10.1 years and 5.0 years, respectively, the numbers who progressed to late AMD, GA, or neovascular AMD were 454 (23.3%), 345 (17.7%), and 278 (14.3%), respectively, in AREDS and 643 (38.0%), 402 (24.6%), and 341 (20.1%) in AREDS2. The hazard ratios of progression in quintile 5 (highest propensity for aspirin use) versus 1 (reference) were 1.17 (P = 0.35), 1.24 (0.25), and 0.95 (0.81), respectively, in AREDS and 1.26 (0.09), 1.46 (0.03), and 1.12 (0.58) in AREDS2. No significant association with progression to late AMD was observed for quintiles 2 through 5 for any of the 3 outcomes in either study. CONCLUSIONS: Aspirin use was not associated significantly with progression to late AMD or its subtypes in either the AREDS or AREDS2. Patients with AMD need not avoid aspirin for this reason when its use is medically indicated.
引用
- Keenan TD, Wiley HE, Agrón E, et al. The Association of Aspirin Use with Age-Related Macular Degeneration Progression in the Age-Related Eye Disease Studies: Age-Related Eye Disease Study 2 Report No. 20. Ophthalmology. 2019. PMID: 31358390. doi:10.1016/j.ophtha.2019.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。